GYRE
Gyre Therapeutics Inc
NASDAQ · Biotechnology
$7.88
+0.37 (+4.93%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 93.97M | 231.94M | 230.03M | 258.04M |
| Net Income | 10.73M | -34,891,358 | -29,454,556 | -30,205,686 |
| EPS | — | — | — | — |
| Profit Margin | 11.4% | -15.0% | -12.8% | -11.7% |
| Rev Growth | +143.3% | -3.5% | +14.1% | +6.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 112.30M | 100.36M | 97.13M |
| Total Equity | — | 448.31M | 485.41M | 472.92M |
| D/E Ratio | — | 0.25 | 0.21 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 20.63M | -32,635,653 | -32,852,234 | -35,942,077 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 | -23,210,699 |